| Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition S Zhao, S Bellone, S Lopez, D Thakral, C Schwab, DP English, J Black, ... Proceedings of the National Academy of Sciences 113 (43), 12238-12243, 2016 | 205 | 2016 |
| The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review G Scaletta, F Plotti, D Luvero, S Capriglione, R Montera, A Miranda, ... Expert review of anticancer therapy 17 (9), 827-839, 2017 | 153 | 2017 |
| Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition SG Vitale, S Capriglione, G Zito, S Lopez, FA Gulino, F Di Guardo, ... Archives of gynecology and obstetrics 299, 299-315, 2019 | 126 | 2019 |
| The role of oxidative stress and membrane transport systems during endometriosis: a fresh look at a busy corner SG Vitale, S Capriglione, I Peterlunger, VL La Rosa, A Vitagliano, ... Oxidative medicine and cellular longevity 2018, 2018 | 121 | 2018 |
| Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients S Bellone, F Centritto, J Black, C Schwab, D English, E Cocco, S Lopez, ... Gynecologic oncology 138 (1), 11-17, 2015 | 82 | 2015 |
| Ten years of HPV vaccines: State of art and controversies R Angioli, S Lopez, A Aloisi, C Terranova, C De Cicco, G Scaletta, ... Critical reviews in oncology/hematology 102, 65-72, 2016 | 79 | 2016 |
| Uterine serous carcinoma G Bogani, I Ray-Coquard, N Concin, NYL Ngoi, P Morice, T Enomoto, ... Gynecologic oncology 162 (1), 226-234, 2021 | 71 | 2021 |
| Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro S Bellone, E Bignotti, S Lonardi, F Ferrari, F Centritto, A Masserdotti, ... Gynecologic oncology 144 (1), 146-152, 2017 | 68 | 2017 |
| Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy L Zammataro, S Lopez, S Bellone, F Pettinella, E Bonazzoli, E Perrone, ... Proceedings of the National Academy of Sciences 116 (45), 22730-22736, 2019 | 66 | 2019 |
| Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study G Bogani, V Di Donato, F Sopracordevole, A Ciavattini, A Ghelardi, ... Gynecologic oncology 159 (3), 636-641, 2020 | 65 | 2020 |
| PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas JD Black, S Lopez, E Cocco, S Bellone, G Altwerger, CL Schwab, ... British journal of cancer 113 (7), 1020-1026, 2015 | 63 | 2015 |
| T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2 R Nicoletti, S Lopez, S Bellone, E Cocco, CL Schwab, JD Black, ... Clinical & experimental metastasis 32, 29-38, 2015 | 60 | 2015 |
| SYD985, a novel duocarmycin-based HER2-targeting antibody–drug conjugate, shows antitumor activity in uterine serous carcinoma with HER2/Neu expression J Black, G Menderes, S Bellone, CL Schwab, E Bonazzoli, F Ferrari, ... Molecular cancer therapeutics 15 (8), 1900-1909, 2016 | 57 | 2016 |
| Clostridium Perfringens Enterotoxin (CPE) and CPE-Binding Domain (c-CPE) for the Detection and Treatment of Gynecologic Cancers JD Black, S Lopez, E Cocco, CL Schwab, DP English, AD Santin Toxins 7 (4), 1116-1125, 2015 | 56 | 2015 |
| Immunotherapy for platinum-resistant ovarian cancer G Bogani, S Lopez, M Mantiero, M Ducceschi, S Bosio, S Ruisi, ... Gynecologic oncology 158 (2), 484-488, 2020 | 55 | 2020 |
| Prevalence and role of HER2 mutations in cancer E Cocco, S Lopez, AD Santin, M Scaltriti Pharmacology & therapeutics 199, 188-196, 2019 | 55 | 2019 |
| Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors C Li, E Bonazzoli, S Bellone, J Choi, W Dong, G Menderes, G Altwerger, ... Proceedings of the National Academy of Sciences 116 (2), 619-624, 2019 | 54 | 2019 |
| T‐DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo DP English, S Bellone, CL Schwab, I Bortolomai, E Bonazzoli, E Cocco, ... Cancer medicine 3 (5), 1256-1265, 2014 | 53 | 2014 |
| Ovarian cancer relapse: from the latest scientific evidence to the best practice D Luvero, F Plotti, A Aloisia, R Montera, C Terranova, CDC Nardone, ... Critical reviews in oncology/hematology 140, 28-38, 2019 | 48 | 2019 |
| High-risk HPV-positive and-negative high-grade cervical dysplasia: Analysis of 5-year outcomes G Bogani, F Sopracordevole, V Di Donato, A Ciavattini, A Ghelardi, ... Gynecologic Oncology 161 (1), 173-178, 2021 | 47 | 2021 |
